ScholarIQanswers from OpenAlex

APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease

PaperCitations, authors & open-access status

APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease is a paper indexed in ScholarIQ from OpenAlex.

How many citations does APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease have?

ScholarIQcitation count

APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease has 122 citations in the OpenAlex counts ScholarIQ stores.

When was APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease published?

ScholarIQyear

APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease has 2011 year in the ScholarIQ index.

What is the open-access status of APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease?

ScholarIQoa status

APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease has green oa status in the ScholarIQ index.

What is the DOI of APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease?

ScholarIQdoi

The DOI for APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease is on the source record.

What is the PMID of APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease?

ScholarIQpmid

The PMID for APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease is on the source record.

What is the OpenAlex record for APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease?

ScholarIQopenalex

The OpenAlex for APOL1 Risk Variants Predict Histopathology and Progression to ESRD in HIV-Related Kidney Disease is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial